No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 triaL

Gastroenterology

Volumn 147, Issue 2, 2014, Pages

  Sanyal, Arun J ^a   Abdelmalek, Manal F ^b   Suzuki, Ayako ^c,d   Cummings, Oscar W ^e   Chojkier, Mario ^f  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^e INDIANA UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ethyl All Cis 5,8,11,14,17 Eicosapentaenoate; Metabolic Syndrome; Triglycerides

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; COLLAGEN TYPE 4; CYTOKERATIN 18; ETHYL EICOSAPENTANOIC ACID; FERRITIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYALURONIC ACID; INSULIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALERIC ACID DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGINA PECTORIS; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; NONALCOHOLIC FATTY LIVER; NORTH AMERICA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ETHYL ALL-CIS-5,8,11,14,17-EICOSAPENTAENOATE; METABOLIC SYNDROME; TRIGLYCERIDES;

BIOPSY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY LIVER; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NORTH AMERICA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 84904661185     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.04.046     Document Type: Article

References (28)

1. J.D. Browning, L.S. Szczepaniak, and R. Dobbins et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
2. J. Ludwig, T.R. Viggiano, and D.B. McGill et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease Mayo Clin Proc 55 1980 434 438
3. B.A. Neuschwander-Tetri, J.M. Clark, and N.M. Bass et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease Hepatology 52 2010 913 924
4. M. Ekstedt, L.E. Franzen, and U.L. Mathiesen et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 2006 865 873
5. A.J. Sanyal, C. Banas, and C. Sargeant et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C Hepatology 43 2006 682 689
6. D.L. White, F. Kanwal, and H.B. El-Serag Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review Clin Gastroenterol Hepatol 10 2012 1342 1359
7. N. Rafiq, C. Bai, and Y. Fang et al. Long-term follow-up of patients with nonalcoholic fatty liver Clin Gastroenterol Hepatol 7 2009 234 238
8. L.A. Adams, J.F. Lymp, and J. St Sauver et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 2005 113 121
9. G. Marchesini, M. Brizi, and A.M. Morselli-Labate et al. Association of nonalcoholic fatty liver disease with insulin resistance Am J Med 107 1999 450 455
10. S. Chitturi, S. Abeygunasekera, and G.C. Farrell et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome Hepatology 35 2002 373 379
11. A. Wieckowska, B.G. Papouchado, and Z. Li et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis Am J Gastroenterol 103 2008 1372 1379
12. P. Puri, R.A. Baillie, and M.M. Wiest et al. A lipidomic analysis of nonalcoholic fatty liver disease Hepatology 46 2007 1081 1090
13. J. Araya, R. Rodrigo, and P. Pettinelli et al. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients Obesity (Silver Spring) 18 2010 1460 1463
14. N. Siriwardhana, N.S. Kalupahana, and N. Moustaid-Moussa Health benefits of n-3 polyunsaturated fatty acids: eicosapentaenoic acid and docosahexaenoic acid Adv Food Nutr Res 65 2012 211 222
15. G. Schmitz, and J. Ecker The opposing effects of n-3 and n-6 fatty acids Prog Lipid Res 47 2008 147 155
16. M.J. Zhang, and M. Spite Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids Annu Rev Nutr 32 2012 203 227
17. T. Kurabayashi, M. Okada, and K. Tanaka Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group Obstet Gynecol 96 2000 521 528
18. N. Tanaka, K. Sano, and A. Horiuchi et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis J Clin Gastroenterol 42 2008 413 418
19. D.E. Kleiner, E.M. Brunt, and M. Van Natta et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
20. M. Phang, M.L. Garg, and A.J. Sinclair Inhibition of platelet aggregation by omega-3 polyunsaturated fatty acids is gender specific-Redefining platelet response to fish oils Prostaglandins Leukot Essent Fatty Acids 81 2009 35 40
21. M.R. Charlton, J.M. Burns, and R.A. Pedersen et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 141 2011 1249 1253
22. A. Sanyal, A. Poklepovic, and E. Moyneur et al. Population-based risk factors and resource utilization for HCC: US perspective Curr Med Res Opin 26 2010 2183 2191
23. I.P. Alwayn, C. Andersson, and B. Zauscher et al. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor Transplantation 79 2005 606 608
24. S.D. Clarke Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription Am J Physiol Gastrointest Liver Physiol 281 2001 G865 G869
25. M. Capanni, F. Calella, and M.R. Biagini et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study Aliment Pharmacol Ther 23 2006 1143 1151
26. P. Angeli, A. Sanyal, and S. Moller et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites Liver Int 33 2013 16 23
27. K.D. Lindor, K.V. Kowdley, and E.J. Heathcote et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 2004 770 778
28. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med;362:1675-1685.